Rosie Fisher
University of Oxford
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Rosie Fisher.
Nature Medicine | 1998
Jonathon M. Tinsley; Nicolas Deconinck; Rosie Fisher; David Kahn; S Phelps; Jean-Marie Gillis; Kay E. Davies
Duchenne muscular dystrophy (DMD) is a lethal, progressive muscle wasting disease caused by a loss of sarcolemmal bound dystrophin, which results in the death of the muscle fiber leading to the gradual depletion of skeletal muscle. The molecular structure of dystrophin is very similar to that of the related protein utrophin. Utrophin is found in all tissues and is confined to the neuromuscular and myotendinous junctions in mature muscle. Sarcolemmal localization of a truncated utrophin transgene in the dystrophin-deficient mdx mouse significantly improves the dystrophic muscle phenotype. Therefore, upregulation of utrophin by drug therapy is a plausible therapeutic approach in the treatment of DMD. Here we demonstrate that expression of full-length utrophin in mdx mice prevents the development of muscular dystrophy. We assessed muscle morphology, fiber regeneration and mechanical properties (force development and resistance to stretch) of mdx and transgenic mdx skeletal and diaphragm muscle. The utrophin levels required in muscle are significantly less than the normal endogenous utrophin levels seen in lung and kidney, and we provide evidence that the pathology depends on the amount of utrophin expression. These results also have important implications for DMD therapies in which utrophin replacement is achieved by delivery using exogenous vectors.
Journal of Cell Science | 2006
Toshifumi Yokota; Qilong Lu; Jennifer E. Morgan; Kay E. Davies; Rosie Fisher; Shin’ichi Takeda; Terence A. Partridge
Duchenne muscular dystrophy and the mdx mouse myopathies reflect a lack of dystrophin in muscles. However, both contain sporadic clusters of revertant fibers (RFs) that express dystrophin. RF clusters expand in size with age in mdx mice. To test the hypothesis that the expansion of clusters is achieved through the process of muscle degeneration and regeneration, we analyzed muscles of mdx mice in which degeneration and regeneration were inhibited by the expression of micro-dystrophins or utrophin transgenes. Postnatal RF expansion was diminished in direct correlation to the protective effect of the transgene expression. Similarly, expansion of RFs was inhibited when muscle regeneration was blocked by irradiation. However, in irradiated muscles, irradiation-tolerant quiescent muscle precursor cells reactivated by notexin effectively restored RF expansion. Our observations demonstrate that revertant events occur initially within a subset of muscle precursor cells. The proliferation of these cells, as part of the regeneration process, leads to the expansion of RF clusters within degenerating muscles. This expansion of revertant clusters depicts the cumulative history of regeneration, thus providing a useful index for functional evaluation of therapies that counteract muscle degeneration.
Neuromuscular Disorders | 2001
Rosie Fisher; Jonathon M. Tinsley; S Phelps; Sarah Squire; Elizabeth R. Townsend; Jo Martin; Kay E. Davies
Duchenne muscular dystrophy (DMD) is an inherited, severe muscle wasting disease caused by the loss of the cytoskeletal protein, dystrophin. Patients usually die in their late teens or early twenties of cardiac or respiratory failure. We have previously demonstrated that the dystrophin related protein, utrophin is able to compensate for the loss of dystrophin in the mdx mouse, the mouse model of the disease. Expression of a utrophin transgene under the control of an HSA promoter results in localization of utrophin to the sarcolemma and prevents the muscle pathology. Here we show that the over-expression of full-length utrophin in a broad range of tissues is not detrimental in the mdx mouse. These findings have important implications for the feasibility of the up-regulation of utrophin in therapy for DMD since they suggest that tissue specific up-regulation may not be necessary.
Nature | 1996
Jonathon M. Tinsley; A Potter; Steven R. Phelps; Rosie Fisher; Jeffrey I. Trickett; Kay E. Davies
Nature Medicine | 1997
Nicolas Deconinck; David Kahn; Jonathon M. Tinsley; Fabienne De Backer; Rosie Fisher; S Phelps; Kay E. Davies; Jean-Marie Gillis
Human Molecular Genetics | 2002
Sarah Squire; Jean-Marc Raymackers; Clarisse Vandebrouck; A Potter; Jonathon M. Tinsley; Rosie Fisher; Jean-Marie Gillis; Kay E. Davies
Genes and Function | 1997
Andrew Ward; Rosie Fisher; Lynne Richardson; Jo‐Anna Pooler; Sarah Squire; Phil Bates; Rimma Shaposhnikov; Neil Hayward; Milo Thurston; Chris Graham
Neuromuscular Disorders | 2007
Kristen J. Nowak; G. Ravenscroft; Connie Jackaman; Esther Lim; Sarah Squire; A Potter; Rosie Fisher; P.J. Morling; Lisa M. Griffiths; John M. Papadimitriou; C. Sewry; V. Fabian; J. Lessard; K. Crawford; Anthony J. Bakker; Kay E. Davies; Nigel G. Laing
Neuromuscular Disorders | 2001
M J Cullen; J Walsh; Jonathon M. Tinsley; Rosie Fisher; Kay E. Davies
American Journal of Human Genetics | 2000
Rosie Fisher; Jonathon M. Tinsley; Phelps; E R Townsend; S E Squire; Kay E. Davies